Covid19NCT04874363
The Effects of Smoking on Mortality in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection
An observational study of Covid19 and Smoking, run by Sisli Hamidiye Etfal Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
This is a retrospective single centered study that was done in the ICU on patients with Covid-19 between 16th of March -16th of May in 2020 Retrospective records will be examined by examining the electronic data files of the patients. There were two groups as smoker and non-smoker. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- How many people
- 150 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Mar 2020to 30 May 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Conditions regarded to the usage of cigarettes will be recorded as patients who are active smokers and patients who do not smoke.
Who may be able to join
- All the patient's data are diagnosed with acute respiratory syndrome Covid-19 over 18 years old
Who cannot join
- Patients under 18 years of age
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Sisli Hamidiye Etfal Research and Training Hospital
Istanbul
About this study
Official title: The Effects of Smoking on Mortality in Intensive Care Unit in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection
This is a retrospective single centered study that was done in the ICU on patients with Covid-19 between 16th of March -16th of May in 2020 Retrospective records will be examined by examining the electronic data files of the patients.
There were two groups as smoker and non-smoker.
Read the detailed description
The aims of the present study is to see the effects of smoking prevalence, the length of stay regarding the usage of cigarettes, and the effects on the mortality of COVID-19 in our intensive care unit(ICU).
This is a retrospective single centered study that was done in the ICU on patients with Covid-19 between 16th of March -16th of May in 2020. The demographic data, comorbidity status, the units they were accepted from, clinical symptoms , respiratory support, prevalence of smoking, length of stay in the ICU and mortalities of the patients weill be recorded. There are two groups as smoker and non-smoker.
- Being tested
- no intervention
- Medical subject headings
- COVID-19, Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
no interventionOther
no intervention
| Study group | Role | What they receive |
|---|---|---|
| smoker | active smokers Receives: Other: no intervention | |
| non-smoker | Patients who have never smoked Receives: Other: no intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
Mortality rates of patients
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2021
- Study start15 Mar 2020
- Primary completion15 May 2020
- Study completion30 May 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Seyhan Metin, Sisli Hamidiye Etfal Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04874363
- Sponsor's protocol ID
- 2810
- Status last verified
- May 2021
- First submitted
- 1 May 2021
- Last updated
- 5 May 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Smoking on Mortality in Intensive Care Unit in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection
- ClinicalTrials.gov ID
- NCT04874363
- Acronym / sponsor ID
- 2810
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Sisli Hamidiye Etfal Training and Research HospitalUniversity, hospital or other
- Study start
- 15 Mar 2020 (actual)
- Primary completion
- 15 May 2020 (actual)
- Study completion
- 30 May 2020 (actual)
- First posted
- 5 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective single centered study that was done in the ICU on patients with Covid-19 between 16th of March -16th of May in 2020 Retrospective records will be examined by examining the electronic data files of the patients.
There were two groups as smoker and non-smoker.
Detailed description
The aims of the present study is to see the effects of smoking prevalence, the length of stay regarding the usage of cigarettes, and the effects on the mortality of COVID-19 in our intensive care unit(ICU).
This is a retrospective single centered study that was done in the ICU on patients with Covid-19 between 16th of March -16th of May in 2020. The demographic data, comorbidity status, the units they were accepted from, clinical symptoms , respiratory support, prevalence of smoking, length of stay in the ICU and mortalities of the patients weill be recorded. There are two groups as smoker and non-smoker.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| smoker | – | Other: no interventionactive smokers |
| non-smoker | – | Other: no interventionPatients who have never smoked |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Conditions regarded to the usage of cigarettes will be recorded as patients who are active smokers and patients who do not smoke.
Key inclusion criteria (1 listed)
- All the patient's data are diagnosed with acute respiratory syndrome Covid-19 over 18 years old
Key exclusion criteria (1 listed)
- Patients under 18 years of age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| no interventionno intervention | Other | non-smoker, smoker |
Primary outcome
Mortality
Time frame: 3 months
Mortality rates of patients
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19 and Smoking, run by Sisli Hamidiye Etfal Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2021.